Crystal Research Associates' Blog

GeoVax announced that it has been nominated for the 2019 ViE (Vaccine Industry Excellence) Awards in three categories. Please use the following link to vote for these special industry awards in the follow categories:

https://www.surveymonkey.co.uk/r/J39ZFW3

Best Vaccine Technology/Platform
Best Therapeutic Vaccine
Best Prophylactic Vaccine

GeoVax's development programs are importantly focused on vaccines against HIV as well as Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa), and malaria. GeoVax also is evaluating the use of its MVA-VLP platform in cancer immunotherapy and for therapeutic use in chronic Hepatitis B infections. .

For more information on GeoVax, please read to our most recent Quarterly Update dated November 14, 2018, as well as our Executive Informational Overview (EIO), issued on June 15, 2017 and available for download below.

*******************************************

Visit our Corporate Profile and Key Points pages

for the latest research on GeoVax Labs, Inc.

*******************************************

CVR Medical Corp. announced today that it has completed a Food and Drug Administration De Novo Submission for its “Carotid Stenotic Scan (CSS)” device. A De Novo Submission allows for a company to receive a “not substantially equivalent” risk-based evaluation for any legally marketed device for which there is no prior, comparable classification.

The Company's CSS, which is a novel device that uses patented sound wave analysis technology to detect and measure carotid arterial stenosis, fits within the criteria of this FDA filing. Due to U.S. government shutdown, the submission will be reviewed by the FDA upon resumption of government activity.

CVR's FDA submission marks the culmination of the Company's many years of product development, design, trials, and organizational preparation, and is necessary for any new device entering the market.

******************************************************

Learn move about CVR Medical by downloading our Executive Informational Overview (EIO), a 60-page report detailing the Company's business, product development, strategic relationships, market opportunities, competition, financials, risks, and more.

GeoVax Labs, Inc. (GOVX-OTC) Nominated for 2019 ViE Awards in Three categories

CVR Medical Corp.: Announces Completion of FDA Submission for CSS Device (CVM-TSX; CRRVF-OTCQB)

About This Blog

Posts by Date

Posts by Topic